Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

SHILPA MEDICARE LTD. - 530549 - Submission In Compliance With Regulation 40(9) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Financial Year Ended 31 March 2023.

 Pursuant to Regulation 40(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a Certificate dated 21 April 2023 for the financial year ended 31 March 2023 issued by CS DS Rao Practicing Company Secretary.
24-04-2023
Bigul

SHILPA MEDICARE LTD. - 530549 - Submission In Compliance With Regulation 76 Of The Securities And Exchange Board Of India (Depositories And Participants) Regulations, 2018 For Quarter Ended 31 March 2023.

 Pursuant to Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find herewith enclosed the Reconciliation of Share Capital Audit Report for Equity Shares dated 20 April, 2023 for the Quarter ended 31 March 2023, issued by CS D.S. Rao, Practicing Company Secretary, Hyderabad.
21-04-2023
Bigul

SHILPA MEDICARE LTD. - 530549 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Certificate for the quarter ended 31 March 2023, certifying that the details of securities dematerialized/rematerialized during the aforesaid period were maintained by 'M/s. Kfin Technologies Limited'
12-04-2023
Bigul

SHILPA MEDICARE LTD. - 530549 - Compliance Certificate For The Period 31St March, 2023

 Compliance Certificate for the period 31st March, 2023
12-04-2023

Shilpa Medicare shares surge 9% on USFDA final nod to psoriatic arthritis drug

 The drug is executed from a contract manufacturing site.
11-04-2023
Bigul

SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited Receives US FDA Approval For Psoriatic Arthritis Drug

 This is to inform you that the Company has received U.S Food and Drug Administration final approval for its ANDA, Apremilast Tablets, 10 mg, 20 mg, and 30 mg for the treatment of adult patients with active psoriatic arthritis. The product is executed from a contract manufacturing site. Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene. According to IQVIA MAT Q4 2022 data, the US market for Apremilast Tablets, 10 mg, 20 mg, and 30 mg is approximately US $ 3.55 Billion.
10-04-2023
Bigul

SHILPA MEDICARE LTD. - 530549 - Closure of Trading Window

 With reference to the above subject, we would like to inform you that pursuant to 'Code of Conduct for Regulating, Monitoring and Reporting Trading by Designated Persons and their Immediate Relatives', the Trading Window for dealing in the securities of the Company shall remain closed for all the designated persons and their immediate relatives as covered under the said Code with effect from 01 April 2023 till 48 hours after the declaration of Audited Financial Results for the quarter/year ended 31 March 2023. Please note that the date of the Board Meeting to be held for the consideration of Audited Financial Results of the Company for the quarter/year ended 31 March 2023 shall be communicated in due course of time.
29-03-2023
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Credit Rating

 Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), we wish to inform you that India Ratings & Research (Ind-Ra) has issued Long-Term Issuer Rating at 'IND A'.
28-03-2023
Bigul

SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg - US FDA Inspection Of Shilpa Medicare Limited, Unit VII, Analytical Services Division

 This is to inform you that the Company's Analytical Services Division situated at Unit 7, Nacharam, Hyderabad, Telangana has been inspected by US FDA during 08 Mar 2023 to 10 Mar 2023. The inspection is closed with 2 minor observations, which are related to improvements in existing procedures and are addressable. The Company will be submitting the responses to US FDA observations within stipulated timeline and will work towards implementing the corrective actions to address the observations.
11-03-2023
Bigul

SHILPA MEDICARE LTD. - 530549 - Clarification On Increase In Volume Of Securities

 With reference to the above, we hereby confirm that the Company has been making prompt disclosures of events or information that have a bearing on the operation /performance of the Company which includes all price sensitive information etc. within the stipulated timelines as required under SEBI (Listing Obligations and Disclosure Requirement), Regulations 2015. To the best of Company''s knowledge, currently there is no such information or event which is price sensitive, which the Company needs to disseminate investors for their information. We further request you to note that since the shares of the Company are freely traded on the Stock Exchanges, the Company will not be in the position to comment on the movement in volume of shares/share price of the Company. This is for your record and information.
10-03-2023
Next Page
Close

Let's Open Free Demat Account